Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Tumour Biol

Retrieve available abstracts of 121 articles:
HTML format
Text format



Single Articles


    July 2017
  1. CHEN H, Deng Z, Huang C, Wu H, et al
    Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression.
    Tumour Biol. 2017;39:1010428317716249.
    PubMed     Text format     Abstract available


  2. ZHU L, Feng H, Jin S, Tan M, et al
    High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317711655.
    PubMed     Text format     Abstract available


  3. YU J, Han Q, Cui Y
    Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial-mesenchymal transition.
    Tumour Biol. 2017;39:1010428317709129.
    PubMed     Text format     Abstract available


    June 2017
  4. CHANG L, Guo R, Yuan Z
    IL-36alpha suppresses proliferation of ovarian cancer cells.
    Tumour Biol. 2017;39:1010428317706918.
    PubMed     Text format     Abstract available


  5. LI Q, Xue X, Li W, Wang Q, et al
    Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues.
    Tumour Biol. 2017;39:1010428317701650.
    PubMed     Text format     Abstract available


  6. SUN H, Shi JX, Zhang HF, Xing MT, et al
    Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Tumour Biol. 2017;39:1010428317699132.
    PubMed     Text format     Abstract available


  7. HUANG L, Zhou Y, Cao XP, Lin JX, et al
    KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis.
    Tumour Biol. 2017;39:1010428317706289.
    PubMed     Text format     Abstract available


  8. PING H, Guo L, Xi J, Wang D, et al
    Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
    Tumour Biol. 2017;39:1010428317713389.
    PubMed     Text format     Abstract available


  9. WANG J, Liu Q, Zhou X, He Y, et al
    Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
    Tumour Biol. 2017;39:1010428317706479.
    PubMed     Text format     Abstract available


    May 2017
  10. LIU T, Zhao L, Hou H, Ding L, et al
    Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals.
    Tumour Biol. 2017;39:1010428317692225.
    PubMed     Text format     Abstract available


  11. WANG LL, Xiu YL, Chen X, Sun KX, et al
    The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.
    Tumour Biol. 2017;39:1010428317706210.
    PubMed     Text format     Abstract available


  12. KOO YJ, Kim TJ, Min KJ, So KA, et al
    CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317706226.
    PubMed     Text format     Abstract available


  13. XU Y, Ma YH, Pang YX, Zhao Z, et al
    Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition.
    Tumour Biol. 2017;39:1010428317701627.
    PubMed     Text format     Abstract available


  14. LI Y, Xiao M, Guo F
    The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.
    Tumour Biol. 2017;39:1010428317705508.
    PubMed     Text format     Abstract available


  15. SU YK, Huang WC, Lee WH, Bamodu OA, et al
    Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.
    Tumour Biol. 2017;39:1010428317691689.
    PubMed     Text format     Abstract available


  16. GASPARRI ML, Casorelli A, Bardhi E, Besharat AR, et al
    Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    Tumour Biol. 2017;39:1010428317695525.
    PubMed     Text format     Abstract available


  17. SADLECKI P, Walentowicz P, Bodnar M, Marszalek A, et al
    Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
    Tumour Biol. 2017;39:1010428317706230.
    PubMed     Text format     Abstract available


    March 2017
  18. CHENG J, Su M, Jin Y, Xi Q, et al
    Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis.
    Tumour Biol. 2017;39:1010428317694543.
    PubMed     Text format     Abstract available


  19. WANG D, Cao X, Zhang Y, Liu Y, et al
    LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
    Tumour Biol. 2017;39:1010428317695014.
    PubMed     Text format     Abstract available


  20. DU Z, Sha X
    Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a.
    Tumour Biol. 2017;39:1010428317694302.
    PubMed     Text format     Abstract available


    February 2017
  21. VALLIUS T, Hynninen J, Auranen A, Matomaki J, et al
    Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317691189.
    PubMed     Text format     Abstract available


  22. DAROOEI M, Poornima S, Salma BU, Iyer GR, et al
    Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
    Tumour Biol. 2017;39:1010428317694303.
    PubMed     Text format     Abstract available


  23. MA L, Zhang W, Ding Z, Wu SG, et al
    Association of a common variant of SYNPO2 gene with increased risk of serous epithelial ovarian cancer.
    Tumour Biol. 2017;39:1010428317691185.
    PubMed     Text format     Abstract available


    November 2016
  24. AZIZMOHAMMADI S, Safari A, Seifoleslami M, Rabati RG, et al
    Retraction Note to: Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Text format    


  25. LIN L, Wang Z, Jin H, Shi H, et al
    MiR-212/132 is epigenetically downregulated by SOX4/EZH2-H3K27me3 feedback loop in ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  26. HOU R, Jiang L, Yang Z, Wang S, et al
    Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  27. ZHANG W, Yang J, Cao D, You Y, et al
    Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  28. HADA M, Subramanian C, Andrews PC, Kwok RP, et al
    Cytosolic Ku70 regulates Bax-mediated cell death.
    Tumour Biol. 2016;37:13903-13914.
    PubMed     Text format     Abstract available


    September 2016
  29. XIAOHONG Z, Lichun F, Na X, Kejian Z, et al
    MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  30. SHEN Y, Li L
    Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  31. MO Q, Zhang Y, Jin X, Gao Y, et al
    Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  32. WATROWSKI R, Heinze G, Jager C, Forster J, et al
    Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.
    Tumour Biol. 2016;37:12079-12087.
    PubMed     Text format     Abstract available


  33. FARKKILA A, Zauli G, Haltia UM, Pihlajoki M, et al
    Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.
    Tumour Biol. 2016;37:11909-11916.
    PubMed     Text format     Abstract available


  34. GAO S, Zhu L, Feng H, Hu Z, et al
    Gene expression profile analysis in response to alpha1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells.
    Tumour Biol. 2016;37:12251-12262.
    PubMed     Text format     Abstract available


    August 2016
  35. SANKPAL UT, Ingersoll SB, Ahmad S, Holloway RW, et al
    Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  36. ZHU Y, Cai L, Guo J, Chen N, et al
    Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  37. LU H, Liu Y, Wang D, Wang L, et al
    Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-kappaB pathway.
    Tumour Biol. 2016;37:11469-77.
    PubMed     Text format     Abstract available


  38. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
    Tumour Biol. 2016;37:10697-702.
    PubMed     Text format     Abstract available


    July 2016
  39. LI Z, Block MS, Vierkant RA, Fogarty ZC, et al
    The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  40. KARLSEN MA, Fago-Olsen C, Hogdall E, Schnack TH, et al
    A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  41. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Jastrzebska J, Menkiszak J, et al
    Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
    Tumour Biol. 2016;37:8879-87.
    PubMed     Text format     Abstract available


    June 2016
  42. DIMITROVA D, Ruscito I, Olek S, Richter R, et al
    Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor B
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  43. YAN Q, Wang F, Miao Y, Wu X, et al
    Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  44. LI N, Zhao X, Wang L, Zhang S, et al
    miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R.
    Tumour Biol. 2016;37:7767-76.
    PubMed     Text format     Abstract available


    May 2016
  45. VESKIMAE K, Staff S, Gronholm A, Pesu M, et al
    Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  46. ZHANG W, Niu C, He W, Hou T, et al
    Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Tumour Biol. 2016;37:6239-54.
    PubMed     Text format     Abstract available


    April 2016
  47. CAI G, Ma X, Chen B, Huang Y, et al
    Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  48. SHI C, Zhang Z
    miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.
    Tumour Biol. 2016;37:5437-43.
    PubMed     Text format     Abstract available


  49. WATROWSKI R, Zeillinger R
    Simple laboratory score improves the preoperative diagnosis of adnexal mass.
    Tumour Biol. 2016;37:4343-9.
    PubMed     Text format     Abstract available


  50. HASBY EA
    Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Tumour Biol. 2016;37:4889-900.
    PubMed     Text format     Abstract available


  51. LOPES-COELHO F, Gouveia-Fernandes S, Goncalves LG, Nunes C, et al
    HNF1beta drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
    Tumour Biol. 2016;37:4813-29.
    PubMed     Text format     Abstract available


    March 2016
  52. ZHANG Y, Hua W, Niu LC, Li SM, et al
    Erratum to: Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
    Tumour Biol. 2016.
    PubMed     Text format    


  53. ZUBERI M, Khan I, Gandhi G, Ray PC, et al
    The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  54. DU F, Li Y, Zhang W, Kale SP, et al
    Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  55. ZHAN L, Zhang Y, Wang W, Song E, et al
    E2F1: a promising regulator in ovarian carcinoma.
    Tumour Biol. 2016;37:2823-31.
    PubMed     Text format     Abstract available


  56. BU M, Shen Y, Seeger WL, An S, et al
    Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
    Tumour Biol. 2016;37:3949-56.
    PubMed     Text format     Abstract available


  57. SHEN DF, Liu X, Yang XF, Fang L, et al
    The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.
    Tumour Biol. 2016;37:2909-24.
    PubMed     Text format     Abstract available


  58. MOMENY M, Ghasemi R, Valenti G, Miranda M, et al
    Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
    Tumour Biol. 2016;37:3913-23.
    PubMed     Text format     Abstract available


  59. EL-GENDI S, Abdelzaher E, Mostafa MF, Sheasha GA, et al
    FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    Tumour Biol. 2016;37:3173-83.
    PubMed     Text format     Abstract available


    February 2016
  60. GUO L, Zhou B, Liu Z, Xu Y, et al
    Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  61. YANG Y, Jiang Y, Wan Y, Zhang L, et al
    UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  62. WU DD, Li XS, Meng XN, Yan J, et al
    MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  63. ZHANG P, Wang C, Cheng L, Zhang P, et al
    Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Tumour Biol. 2016;37:2183-91.
    PubMed     Text format     Abstract available


    January 2016
  64. LIU H, Shi H, Fan Q, Sun X, et al
    Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  65. LIU S, Sun J, Cai B, Xi X, et al
    NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  66. ZHANG Y, Hua W, Niu LC, Li SM, et al
    Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  67. CHEN W, Huang L, Hao C, Zeng W, et al
    MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  68. SO WK, Cheng JC, Liu Y, Xu C, et al
    Sprouty4 mediates amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  69. XIA B, Li H, Yang S, Liu T, et al
    MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  70. RUSCITO I, Gasparri ML, Marchetti C, De Medici C, et al
    Cediranib in ovarian cancer: state of the art and future perspectives.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  71. XU L, Zhang X, Li Y, Lu S, et al
    Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/ JNK activation.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  72. CHEN Y, Chen Q, Liu Q, Gao F, et al
    Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.
    Tumour Biol. 2016.
    PubMed     Text format     Abstract available


  73. BHASKARI J, Premalata CS, Shilpa V, Rahul B, et al
    Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers.
    Tumour Biol. 2016;37:1017-23.
    PubMed     Text format     Abstract available


  74. YAN J, Zhang Y, Shi W, Ren C, et al
    The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.
    Tumour Biol. 2016;37:823-8.
    PubMed     Text format     Abstract available


    December 2015
  75. LIU Y, Zhou H, Ma L, Hou Y, et al
    MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  76. LI E, Hu Z, Sun Y, Zhou Q, et al
    Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  77. WATROWSKI R, Castillo-Tong DC, Schuster E, Fischer MB, et al
    Association of HER2 codon 655 polymorphism with ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  78. ZHOU X, Teng L, Wang M
    Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  79. FAN JY, Yang Y, Xie JY, Lu YL, et al
    MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  80. AZIZMOHAMMADI S, Safari A, Seifoleslami M, Rabati RG, et al
    Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  81. WEI X, Jin Y, Tian Y, Zhang H, et al
    Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  82. FU X, Cui Y, Yang S, Xu Y, et al
    MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  83. TANG XH, Deng S, Li M, Lu MS, et al
    Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  84. LABANI-MOTLAGH A, Israelsson P, Ottander U, Lundin E, et al
    Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  85. CUI YY, Yan L, Zhou J, Zhao S, et al
    The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  86. SHAN W, Li J, Bai Y, Lu X, et al
    miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  87. QU QX, Huang Q, Shen Y, Zhu YB, et al
    The increase of circulating PD-L1-expressing CD68 macrophage in ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  88. YU AS, Zhao L
    Effects of the GSK-3beta inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  89. LI J, Yang S, Su N, Wang Y, et al
    Erratum to: Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format    


  90. XU W, Gu J, Ren Q, Shi Y, et al
    NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  91. GASPARRI ML, Savone D, Besharat RA, Farooqi AA, et al
    Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  92. ZHANG W, Peng P, Kuang Y, Yang J, et al
    Characterization of exosomes derived from ovarian cancer cells and normal ovarian epithelial cells by nanoparticle tracking analysis.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  93. KAPLAN F, Teksen F
    Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3).
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  94. JIA J, Wang Z, Cai J, Zhang Y, et al
    PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  95. NASSIR M, Guan J, Luketina H, Siepmann T, et al
    The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  96. LV Q, Sun H, Cao C, Gao B, et al
    Overexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1) are associated with poor prognosis of epithelial ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  97. SAMUEL P, Pink RC, Caley DP, Currie JM, et al
    Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  98. GRANATO T, Manganaro L, Petri L, Porpora MG, et al
    Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  99. LI J, Yang S, Su N, Wang Y, et al
    Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/beta-catenin pathway in human ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  100. LIU C, Yang F
    Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma.
    Tumour Biol. 2015;36:7213-9.
    PubMed     Text format     Abstract available


    August 2015
  101. ZHANG D, Xia H, Zhang W, Fang B, et al
    The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  102. EL-SENDUNY FF, Badria FA, El-Waseef AM, Chauhan SC, et al
    Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  103. YAMAGUCHI N, Mimoto R, Yanaihara N, Imawari Y, et al
    DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Tumour Biol. 2015;36:5913-23.
    PubMed     Text format     Abstract available


    July 2015
  104. LI Y, Chen K, Li L, Li R, et al
    Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  105. LI X, Hu JL, Zhu LM, Sun XH, et al
    The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions.
    Tumour Biol. 2015;36:5515-22.
    PubMed     Text format     Abstract available


  106. LI X, Zheng S, Chen S, Qin F, et al
    Trends in gynaecological cancers in the largest obstetrics and gynaecology hospital in China from 2003 to 2013.
    Tumour Biol. 2015;36:4961-6.
    PubMed     Text format     Abstract available


    June 2015
  107. MICHALSKA MM, Samulak D, Romanowicz H, Bienkiewicz J, et al
    Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  108. OLIVEIRA-FERRER L, Hessling A, Trillsch F, Mahner S, et al
    Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  109. YAN F, Wang X, Shao L, Ge M, et al
    Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  110. ZHANG WW, Liu KJ, Hu GL, Liang WJ, et al
    Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  111. DOBRZYCKA B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, et al
    Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.
    Tumour Biol. 2015;36:4157-65.
    PubMed     Text format     Abstract available


    May 2015
  112. ZHANG C, Qiu X
    Andrographolide radiosensitizes human ovarian cancer SKOV3 xenografts due to an enhanced apoptosis and autophagy.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


  113. LIU Y, Zheng D, Liu M, Bai J, et al
    Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
    Tumour Biol. 2015.
    PubMed     Text format     Abstract available


    April 2015
  114. ZHANG F, Song X, Li L, Wang J, et al
    Polygala tenuifolia polysaccharide (PTP) inhibits cell proliferation by repressing Bmi-1 expression and downregulating telomerase activity.
    Tumour Biol. 2015;36:2907-12.
    PubMed     Text format     Abstract available


  115. NALLAPALLE SR, Daripally S, Prasad VT
    Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.
    Tumour Biol. 2015;36:2709-24.
    PubMed     Text format     Abstract available


  116. ZHUANG H, Tan M, Liu J, Li X, et al
    The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them.
    Tumour Biol. 2015;36:2343-9.
    PubMed     Text format     Abstract available


    March 2015
  117. YU H, Zhang L, Liu P
    CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas.
    Tumour Biol. 2015;36:1679-83.
    PubMed     Text format     Abstract available


    February 2015
  118. SUNG CK, Yim H
    The tumor suppressor protein p150(Sal2) in carcinogenesis.
    Tumour Biol. 2015;36:489-94.
    PubMed     Text format     Abstract available


  119. LI J, Yu H, Xi M, Ma D, et al
    The SNAI1 3'UTR functions as a sponge for multiple migration-/invasion-related microRNAs.
    Tumour Biol. 2015;36:1067-72.
    PubMed     Text format     Abstract available


  120. SANTALA S, Talvensaari-Mattila A, Soini Y, Santala M, et al
    Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.
    Tumour Biol. 2015;36:953-7.
    PubMed     Text format     Abstract available


  121. CHENG S, Guo J, Yang Q, Han L, et al
    Crk-like adapter protein is required for TGF-beta-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.
    Tumour Biol. 2015;36:915-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: